Literature DB >> 17091341

Pharmacokinetics of orally administered tetrahydrobiopterin in patients with phenylalanine hydroxylase deficiency.

M R Zurflüh1, L Fiori, B Fiege, I Ozen, M Demirkol, K H Gärtner, B Thöny, M Giovannini, N Blau.   

Abstract

The oral loading test with tetrahydrobiopterin (BH(4)) is used to discriminate between variants of hyperphenylalaninaemia and to detect BH(4)-responsive patients. The outcome of the loading test depends on the genotype, dosage of BH(4), and BH(4) pharmacokinetics. A total of 71 patients with hyperphenylalaninaemia (mild to classic) were challenged with BH(4) (20 mg/kg) according to different protocols (1 x 20 mg or 2 x 20 mg) and blood BH(4) concentrations were measured in dried blood spots at different time points (T(0), T(2), T(4), T(8), T(12), T(24), T(32) and T(48 h)). Maximal BH(4) concentrations (median 22.69 nmol/g Hb) were measured 4 h after BH(4) administration in 63 out of 71 patients. Eight patients presented with maximal BH(4) concentrations approximately 44% higher at 8 h than at 4 h. After 24 h, BH(4) blood concentrations dropped to 11% of maximal values. This profile was similar using different protocols. The following pharmacokinetic parameters were calculated for BH(4) in blood: t (max) = 4 h, AUC (T(0-32)) = 370 nmol x h/g Hb, and t (1/2) for absorption (1.1 h), distribution (2.5 h), and elimination (46.0 h) phases. Maximal BH(4) blood concentrations were not significantly lower in non-responders and there was no correlation between blood concentrations and responsiveness. Of mild PKU patients, 97% responded to BH(4) administration, while one was found to be a non-responder. Only 10/19 patients (53%) with Phe concentrations of 600-1200 mumol/L responded to BH(4) administration, and of the patients with the severe classical phenotype (blood Phe > 1200 mumol/L) only 4 out of 17 patient responded. An additional 36 patients with mild hyperphenylalaninaemia (HPA) who underwent the combined loading test with Phe+BH(4) were all responders. Slow responders and non-responders were found in all groups of HPA.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17091341     DOI: 10.1007/s10545-006-0425-6

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  22 in total

1.  High frequency of tetrahydrobiopterin-responsiveness among hyperphenylalaninemias: a study of 1,919 patients observed from 1988 to 2002.

Authors:  Caroline Bernegger; Nenad Blau
Journal:  Mol Genet Metab       Date:  2002-12       Impact factor: 4.797

2.  Tetrahydrobiopterin-responsive phenylketonuria: the New South Wales experience.

Authors:  John J Mitchell; Bridget Wilcken; Ian Alexander; Carolyn Ellaway; Helen O'Grady; Veronica Wiley; John Earl; John Christodoulou
Journal:  Mol Genet Metab       Date:  2005-08-08       Impact factor: 4.797

3.  Tetrahydrobiopterin responsiveness in patients with phenylketonuria.

Authors:  Belén Pérez-Dueñas; Maria Antonia Vilaseca; Anna Mas; Nilo Lambruschini; Rafael Artuch; Lilian Gómez; Julia Pineda; Alejandra Gutiérrez; Montse Mila; Jaume Campistol
Journal:  Clin Biochem       Date:  2004-12       Impact factor: 3.281

4.  Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency.

Authors:  S Kure; D C Hou; T Ohura; H Iwamoto; S Suzuki; N Sugiyama; O Sakamoto; K Fujii; Y Matsubara; K Narisawa
Journal:  J Pediatr       Date:  1999-09       Impact factor: 4.406

5.  Long-term treatment and diagnosis of tetrahydrobiopterin-responsive hyperphenylalaninemia with a mutant phenylalanine hydroxylase gene.

Authors:  Haruo Shintaku; Shigeo Kure; Toshihiro Ohura; Yoshiyuki Okano; Misao Ohwada; Naruji Sugiyama; Nobuo Sakura; Ichiro Yoshida; Makoto Yoshino; Yoichi Matsubara; Ken Suzuki; Kikumaro Aoki; Teruo Kitagawa
Journal:  Pediatr Res       Date:  2003-12-17       Impact factor: 3.756

6.  A hypothesis on the biochemical mechanism of BH(4)-responsiveness in phenylalanine hydroxylase deficiency.

Authors:  R Steinfeld; A Kohlschütter; K Ullrich; Z Lukacs
Journal:  Amino Acids       Date:  2003-07       Impact factor: 3.520

7.  Potential role of tetrahydrobiopterin in the treatment of maternal phenylketonuria.

Authors:  Friedrich K Trefz; Nenad Blau
Journal:  Pediatrics       Date:  2003-12       Impact factor: 7.124

8.  Biopterin responsive phenylalanine hydroxylase deficiency.

Authors:  Reuben Matalon; Richard Koch; Kimberlee Michals-Matalon; Kathryn Moseley; Sankar Surendran; Stephen Tyring; Heidi Erlandsen; Alejandra Gamez; Raymond C Stevens; Anne Romstad; Lisbeth B Møller; Flemming Guttler
Journal:  Genet Med       Date:  2004 Jan-Feb       Impact factor: 8.822

9.  Hyperphenylalaninemia and pterin metabolism in serum and erythrocytes.

Authors:  A Ponzone; O Guardamagna; M Spada; R Ponzone; M Sartore; L Kierat; C W Heizmann; N Blau
Journal:  Clin Chim Acta       Date:  1993-07-16       Impact factor: 3.786

Review 10.  The metabolic and molecular bases of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency.

Authors:  Nenad Blau; Heidi Erlandsen
Journal:  Mol Genet Metab       Date:  2004-06       Impact factor: 4.797

View more
  5 in total

1.  Classifying tetrahydrobiopterin responsiveness in the hyperphenylalaninaemias.

Authors:  U Langenbeck
Journal:  J Inherit Metab Dis       Date:  2008-01-22       Impact factor: 4.982

2.  Pharmacokinetics of tetrahydrobiopterin following oral loadings with three single dosages in patients with phenylketonuria.

Authors:  G Gramer; S F Garbade; N Blau; M Lindner
Journal:  J Inherit Metab Dis       Date:  2008-11-21       Impact factor: 4.982

3.  Effects and clinical significance of tetrahydrobiopterin supplementation in phenylalanine hydroxylase-deficient hyperphenylalaninaemia.

Authors:  G Gramer; P Burgard; S F Garbade; M Lindner
Journal:  J Inherit Metab Dis       Date:  2007-08-06       Impact factor: 4.982

Review 4.  The complete European guidelines on phenylketonuria: diagnosis and treatment.

Authors:  A M J van Wegberg; A MacDonald; K Ahring; A Bélanger-Quintana; N Blau; A M Bosch; A Burlina; J Campistol; F Feillet; M Giżewska; S C Huijbregts; S Kearney; V Leuzzi; F Maillot; A C Muntau; M van Rijn; F Trefz; J H Walter; F J van Spronsen
Journal:  Orphanet J Rare Dis       Date:  2017-10-12       Impact factor: 4.123

5.  Pretreatment cognitive and neural differences between sapropterin dihydrochloride responders and non-responders with phenylketonuria.

Authors:  Zoë Hawks; Joshua Shimony; Jerrel Rutlin; Dorothy K Grange; Shawn E Christ; Desirée A White
Journal:  Mol Genet Metab Rep       Date:  2017-02-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.